To prospectively assess whether periodic chest health surveillance is beneficial for the early detection of bronchiolitis obliterans syndrome (BOS) in children after allo-SCT. Children up to 18 years of age receiving allo-SCT from September 2009 to September 2011 were included. Surveillance consisted of the following: a 7-item respiratory system questionnaire of cough, wheeze and shortness of breath; focused physical examination; and pulmonary function test (PFT) conducted before SCT and at 1, 3, 6, 9, 12, 18 and 24 months after SCT. Thirty-nine patients were enrolled. Five children developed BOS at a median time of 192 days (range 94-282). Positive response comparisons between the BOS group vs the non-BOS group were NS for history questionnaire (P ¼ 0.2), heart rate (P ¼ 0.3), respiratory rate (P ¼ 0.3) and oxygen saturation monitoring (P ¼ 0.8). Differences between the two groups for chest auscultation and PFT were statistically significant (P ¼ 0.03 and P ¼ 0.01, respectively). However, chest auscultation in the BOS group was only positive after BOS diagnosis. PFT reduction was evident in the asymptomatic phase (BOS group 33%; non-BOS group 4.5%, P ¼ 0.01). Changes in PFT, but not history/physical examination, allow the early detection of BOS in children after SCT. Our study is limited by the small sample size.
INTRODUCTION
Bronchiolitis obliterans syndrome (BOS) is a well-recognized noninfectious complication of SCT, with significant morbidity and mortality both in adults and children. 1 It is characterized by luminal occlusion of the terminal and respiratory bronchioles caused by inflammatory and fibrous tissue formation. In severe cases, the airway develops circumferential scarring with complete obliteration of the lumen, leading to the clinical presentation of cough, shortness of breath or wheezing. 2, 3 BOS usually occurs in the first 2 years after SCT 4 and leads to high risk of death, with mortality rates reported between 13 and 100% in adults 5, 6 and 40 and 60% in children. 7, 8 Early detection is key for successful stabilization of the disease with immunosuppressant therapy before occurrence of end-stage fibrotic changes with significant reduction in pulmonary function tests (PFTs). 9 The National Cancer Institute, National Heart, Lung and Blood Institute and Pediatric Blood and Marrow Transplantation Consortium have recently published the first International consensus conference report for pediatric-specific long-term follow-up guidelines following SCT. 10 In that report, there is an acknowledgment that early recognition and treatment of pulmonary conditions after SCT is important for successful outcome, and thus increased surveillance for lung dysfunction by serial PFTs for the first 2 years after SCT should be considered whenever feasible. Recommendations from the Joint Transplant Society (CIBMTR, ASBMT, EBMT, APBMT, BMTSANZ, EMBMT and SBTMO) suggest routine clinical evaluation at 6 months and 1 year after SCT and at least yearly thereafter. The Expert panel recommended PFTs for allogeneic recipients twice per year for 2 years, with consideration for more frequent screening in recipients of mismatched or unrelated donor grafts, or patients with active chronic GVHD. After 2 years, consideration for a yearly follow-up PFT on the basis of symptoms and past measurements was suggested. Although PFT changes are the mainstay for BOS diagnosis, some children cannot undergo PFTs owing to young age and lack of cooperation, and pose a significant challenge for monitoring after allo-SCT in terms of early diagnosis of BOS. We hypothesized that a focused respiratory history and clinical evaluation may be useful for the early diagnosis of BOS. Our objectives in this prospective study were to test the utility of a standardized schedule of chest-specific history, clinical examination and PFTs in children after allo-SCT for the early diagnosis of BOS.
PATIENTS AND METHODS
The study was approved by the institutional research ethics board at The Hospital for Sick Children (SickKids), and informed consent/assent was obtained from parents and their children. Children (0-18 years) receiving allo-SCT in SickKids, Toronto, from any donor were eligible. We excluded children who received their follow-up care outside SickKids. The consenting participant (parent or child) has to speak and understand English to be eligible for the study. Patients who agreed to participate in the study had their demographics collected, including age, gender, diagnosis, donor source, conditioning regimen and GVHD prophylaxis. Chest health surveillance was implemented at the following eight time points: before SCT and 1, 3, 6, 9, 12, 18 and 24 months after SCT. At each time point, a 7-item respiratory questionnaire was administered that evaluated cough, shortness of breath and wheezing using a four-point liker scale for the frequency of symptoms: almost every day, several days a week, several days a month and not at all. The questionnaire also addressed whether any of the symptoms may be related to a respiratory tract infection and allowed for other comments related to any other symptoms. This questionnaire was interviewer administered by a consistent clinical research associate. Respondents were parents/legal guardian for young children or participants themselves if they are old enough to understand the questions. At each time point, there was also a focused respiratory system examination, which included chest inspection, palpation and auscultation, monitoring of heart, respiratory rate and transcutaneous oxygen saturation monitoring. The examination was conducted by an experienced dedicated SCT physician. Patients older than 7 years of age had complete standard PFTs assessing lung volumes, capacities, rates of flow and gas exchange at each time point. Table 1 describes the chest health surveillance protocol. In addition to the occurrence of BOS, other outcomes including time to engraftment, infections, GVHD and survival were collected. Development of BOS was either based on histology from lung biopsy or an irreversible decline in FEV1 (forced expiratory volume in one second) of at least 20% from baseline 11 and the new National Institutes of Health consensus criteria (absence of active infection, decreased FEV1 o75% of predicted normal and evidence of airway obstruction with a ratio of FEV1 to forced vital capacity of o0.7 (ref. 1212) with characteristic high-resolution computed tomography imaging. These included air trapping, mosaic perfusion, bronchial dilatation (bronchiectasis) and bronchial wall thickening. 13 Comparison of FEV1 for affected patients was done on the basis of the pre-SCT value and the last value just before the diagnosis of BOS. For nonaffected patients, all PFTs values from pre-SCT to the last follow-up were analyzed. The day of engraftment was defined as the first of 3 consecutive days in which the peripheral ANC was 40.5 Â 10 9 /L.
Analysis
For the 7-item history questions, responses to the questions related to cough, shortness of breath and wheezing were classified as positive if the respondent answered 'almost every day' or 'several days a week'. On chest examination, the presence of wheezes or crackles in the absence of symptoms and signs of an upper or lower respiratory tract infection were considered positive findings. Transcutaneous oxygen saturation below 94% was considered positive. The outcomes between BOS and non-BOS patients were compared by using the last value obtained before the BOS diagnosis for cases and the last value obtained during the observation period for non-BOS patients. Differences in continuous outcomes between the two groups were compared using the Wilcoxon rank-sum test. Categorical variables were compared using the w 2 -test or Fisher's exact test as appropriate.
RESULTS
Between September 2009 and September 2011, 82 children undergoing allo-SCT were eligible; 27 were excluded because they were being followed up elsewhere, 4 had a language barrier and 9 did not agree to participate, leaving a total of 42 children consenting for the study. Three children withdrew from the study at 3, 6 and 12 months after SCT. This resulted in a modest sample of 39 children in the study. Patient demographics are outlined in Table 2 . Twenty-seven children received SCT for malignant disease and twelve for a non-malignant diagnosis. All patients with malignant diseases were in morphological remission before SCT. Two patients died before neutrophil engraftment, and two patients failed to engraft. The remaining patients engrafted at a median of 26 days after SCT (range 12-67). At a median follow-up time of 1.77 years (range 0.86, 2.95), 11 patients had died: 4 from leukemia relapse and 7 from transplant-related complications. The course of two patients with engraftment failure was complicated by an invasive adenovirus in one and VZV in another. They both received unrelated cord stem cells and suffered primary engraftment failure. Attempts for a salvage haploidentical SCT failed. Three patients died from acute pulmonary toxicity, and in one of them CMV was recovered from bronchoalveolar lavage. One patient died from multiorgan failure, and the last patient died from severe chronic GVHD with progressive BOS 11 months after SCT. Eight patients were treated for grade II or more acute GVHD.
Five patients developed BOS at a median time of 192 days (range 94-282). All five patients were older than 7 years of age and performed PFTs at the specified time points. Two patients had lung biopsies that were reported as BOS. The other three patients had 420% reduction in their FEV1compared with baseline and FEV1 o75% predicted, evidence of airway obstruction with FEV1/forced vital capacity o0.7 (0.45, 0.66, 0.66) and absence of active infection with characteristic computed tomography findings. Positive response comparisons between the BOS group vs non-BOS group were NS for history questionnaire (P ¼ 0.2), heart 8) . Differences between the two groups for chest auscultation and PFT were statistically significant (P ¼ 0.03 and P ¼ 0.01, respectively). However, chest auscultation in the BOS group was only positive after BOS diagnosis. PFT reduction, however, was evident in the asymptomatic phase (BOS group 33%; non BOS group 4.5%; P ¼ 0.01). Median time from last PFT that met the BOS diagnostic criteria (FEV1 20% from baseline or 75% predicted) to BOS diagnosis in the five patients was 6 days (range 3-11), allowing time for further work-up to rule out infections that included nasopharyngeal swabs and bronchoalveolar lavage in three patients. All patients had chest computed tomography scans, and in two patients an open lung biopsy was undertaken to make a final diagnosis of BOS. Chest health surveillance results are summarized in Table 3 . For the five affected patients, three patients were diagnosed with BOS B6 months after SCT; their 3 months chest health surveillance and chest examination were normal. One of them had an acute respiratory deterioration 4 months after SCT, which warranted intensive care admission. Infection screening was negative, the patient responded to steroid therapy, and at a later date (6 months following SCT) he underwent an open lung biopsy that demonstrated BOS. Another patient was diagnosed with BOS B9 months after SCT, and his 3 and 6 month chest assessments were also normal. The last patient who was diagnosed with BOS B3 months after SCT had an acute respiratory deterioration 2 months after SCT with negative infection screen, but lung biopsy at 3 months after SCT showed BOS. He responded well to steroids. Apart from the two patients who had a history of acute respiratory deterioration and subsequently were diagnosed with BOS, the remaining three patients were completely asymptomatic until significant reduction in PFTs was identified and a diagnosis of BOS was made. Only at that point was history positive with dry cough or shortness of breath, and chest examination revealed wheezes and fine crackles on auscultation. Only two of the five patients had clinical GVHD with BOS: one had liver GVHD and the other patient had a multisystem severe GVHD. All five affected patients were treated, as soon as the diagnosis of BOS was made, with a pulse of steroids (20 mg/kg daily for 3 days) given monthly for 3 months plus a maintenance dose of 1-2 mg/kg/day for 1-2 months and thereafter until stabilization of PFTs (two patients), or 1-2 mg/kg/ day steroid therapy for 3-6 months (three patients). Cyclosporin, tacrolimus, mycophenolate mofetil, gleevec, azithromycin and inhaled steroids with inhaled ventolin were tried at different times for different patients. One patient died from progressive BOS and multisystem chronic GVHD 11 months post SCT. Four of the five affected patients are still alive and asymptomatic despite their PFTs reduction (stabilized).
DISCUSSION
In this prospective study, we found that a standardized schedule of detailed history questionnaire and detailed chest physical examination and oxygen saturation monitoring at regular intervals were not useful for the early diagnosis of BOS. Patients with BOS only became symptomatic after a significant reduction in their PFTs that met the diagnostic criteria for BOS. Furthermore, as performing PFTs requires a degree of cooperation that is age dependent, only children who are older than 7 years of age were diagnosed with BOS on the basis of PFTs results. Recent reports suggest that BOS after allo-SCT is five times more prevalent than previous estimates, with a prevalence of 14% among survivors, in particular those who develop chronic GVHD. 14 PFTs are the mainstay for the diagnosis of BOS. 11, 12 Nonetheless, the main challenge associated with PFTs following SCT in children is that some children are either too young to undergo the test or uncooperative. Hence, our study is the first pediatric study addressing whether a rigorous post-SCT chest-standardized schedule that takes into consideration history and clinical examination is helpful in the early detection of BOS and before the development of advanced disease. Our results suggest that only PFTs are reliable to diagnose BOS early and may identify potential asymptomatic patients, and that in those who cannot undergo PFT, especially young children, novel alternative techniques such as multiple-breath washout testing needs to be explored. 15, 16 As our understanding about the pathophysiology of BOS is improving, and more patients are surviving longer after SCT with GVHD, The National Institutes of Health consensus group recommends consideration of PFTs or spirometry every 3 months during the first year after transplantation in high-risk patients (patients with chronic GVHD). 12 Regular PFTs in the first year after SCT should allow the capture of subtle changes in lung volumes during a period of tapering immunosuppressant agents when most cases of BOS will start to develop and thus allow an opportunity for earlier and most effective intervention. Although chronic GVHD is a major risk for BOS development post allo-SCT, BOS can be the only presenting feature of chronic GVHD. Furthermore, patients who are at a lower risk for the development of chronic GVHD, such as matched sibling SCT recipients, still develop BOS. Therefore, intensive BOS surveillance should be considered for all patients after allo-SCT in the first 2 years. Three of the five patients affected with BOS in our study had no other stigmata of GVHD.
Furthermore, two of the five affected patients in our study had acute respiratory deterioration 1 and 2 months before the development of BOS (biopsy proven). Although infection screening did not reveal a positive microbiological result, the clinical picture was very suggestive of acute respiratory tract infection. Such possible infection in the setting of early post-SCT donor lymphocyte recovery that lacks the appropriate regulatory mechanism is the perfect example of the allo-lung syndrome. 17 In this recent report of 110 children post SCT, 27.3% had allo-lung syndrome, 2/3 with idiopathic pneumonia syndrome and 1/3 with BOS. Multivariate analysis showed that respiratory viral infection early after SCT was an important predictor for the development of allo-lung syndrome (Po0.0001), and prolonged administration of immunosuppressive agents had a protective effect on the development of allo-lung syndrome (P ¼ 0.004). Although the definition of BOS continues to be as 'non-infectious', early post-SCT infections may have a vital role in its development, and patients with clinical respiratory infection with or without positive microbiological results after SCT should be considered to be at a higher risk for BOS development and deserve a close follow-up with rigorous chest health surveillance.
An important strength of our study is the attempt to utilize a standardized regular simple chest clinical surveillance in order to answer the question of whether a controlled clinical assessment will aid in the early diagnosis of BOS in children post SCT. Our study concluded that clinical assessment alone was not enough to aid in the early diagnosis of BOS. Another strength of our study was the use of simple non-harm screening methods for BOS, which included history, physical examination and PFTs in children post SCT compared with other methods of screening such as regular computed tomography scans of the chest that is associated with increased risk of radiation associated complication and increase risk of cancers in pediatric population. 18 One limitation of our study was the small sample size; however, even with the modest sample of 39 children, PFT differences in BOS and non-BOS patients were statistically significant, but history and clinical examination were not beneficial for the early detection of BOS, and in children in whom PFT cannot be performed other strategies need to be explored or diagnosis of BOS may be delayed leading to inferior outcome. Moreover, owing to our intensive chest surveillance protocol, we were able to stabilize four out of the five affected patients and prevented the advanced fibrotic-stage BOS.
In summary, our study emphasizes the importance of frequent PFTs early after SCT as the only sensitive way to diagnose BOS in children early after SCT. Detailed history and detailed clinical examination were not useful for early diagnosis. Patients with early post-SCT respiratory infection require very close follow-up. Research needs to focus on finding reliable techniques for young children who are unable to perform standard PFTs. Furthermore, with the use of more mismatched SCT donors and higher-risk patients, incidence of BOS post SCT is increasing and more research for potential serum markers for the development of BOS is needed.
